key: cord-0757808-7ew6lrvh
authors: Nutho, Bodee; Mahalapbutr, Panupong; Hengphasatporn, Kowit; Pattaranggoon, Nawanwat Chainuwong; Simanon, Nattapon; Shigeta, Yasuteru; Hannongbua, Supot; Rungrotmongkol, Thanyada
title: Why Are Lopinavir and Ritonavir Effective against the Newly Emerged Coronavirus 2019? Atomistic Insights into the Inhibitory Mechanisms
date: 2020-04-15
journal: Biochemistry
DOI: 10.1021/acs.biochem.0c00160
sha: 6091a8b95defbd25bad60142e0e80ef2d8096885
doc_id: 757808
cord_uid: 7ew6lrvh

[Image: see text] Since the emergence of a novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported from Wuhan, China, neither a specific vaccine nor an antiviral drug against SARS-CoV-2 has become available. However, a combination of two HIV-1 protease inhibitors, lopinavir and ritonavir, has been found to be effective against SARS-CoV, and both drugs could bind well to the SARS-CoV 3C-like protease (SARS-CoV 3CL(pro)). In this work, molecular complexation between each inhibitor and SARS-CoV-2 3CL(pro) was studied using all-atom molecular dynamics simulations, free energy calculations, and pair interaction energy analyses based on MM/PB(GB)SA and FMO-MP2/PCM/6-31G* methods. Both anti-HIV drugs interacted well with the residues at the active site of SARS-CoV-2 3CL(pro). Ritonavir showed a somewhat higher number atomic contacts, a somewhat higher binding efficiency, and a somewhat higher number of key binding residues compared to lopinavir, which correspond with the slightly lower water accessibility at the 3CL(pro) active site. In addition, only ritonavir could interact with the oxyanion hole residues N142 and G143 via the formation of two hydrogen bonds. The interactions in terms of electrostatics, dispersion, and charge transfer played an important role in the drug binding. The obtained results demonstrated how repurposed anti-HIV drugs could be used to combat COVID-19.

I n December 2019, there were many cases of patients reported to have a respiratory tract infection with severe pneumonia in Wuhan, China. It was found that these patients most likely had an epidemiological history related to a seafood market in that area of China. 1 However, a newly causative microbial infection cannot at first be identified in public databases. On the basis of whole genome sequencing, it was revealed that this microbial pathogen is a novel coronavirus, formally named 2019-nCoV, closely related to the bat severe acute respiratory syndrome (SARS)-like coronavirus, so-called SARS-CoV-2. 2, 3 The World Health Organization (WHO) has officially confirmed the outbreak of 2019-nCoV on December 31, 2019, and eventually officially named it coronavirus disease 2019 or COVID-19. In general, coronaviruses are characterized as enveloped, positivesense, single-stranded RNA viruses in the genus Coronavirus of the family Coronaviridae and can infect humans and several animals, including mammals and birds. 4−7 Nonetheless, some coronaviruses can potentially cause severe infection in patients such as the well-known outbreak of SARS-CoV in Guangdong, China, 8 and Middle East respiratory syndrome coronavirus (MERS-CoV) in many countries of the Middle East. 9 Likewise, COVID-19 has been confirmed to be transmitted from humans to humans and quickly spread in several countries throughout the world. 10 SARS-CoV-2 is a betacoronavirus, like SARS-CoV and MERS-CoV, both of which have their origins in bats. 11 For the clinical symptoms, COVID-19 infection culminates in fatal pneumonia with the clinical presentation greatly resembling SARS-CoV infection. 1 Patients infected with SARS-CoV-2 might also develop acute respiratory distress syndrome, leading to a high rate of admission to intensive care units and ultimately death in severe cases. 7 After infection, patients presented mild to severe symptoms, including fever, cough, sore throat, rhinorrhea, severe pneumonia, and septic shock. 1, 7 To date, many companies and academic research groups around the world have focused on searching for and developing a specific vaccine or antiviral drug to prevent or control emerging SARS-CoV-2 infections (e.g., vaccine, monoclonal antibodies, and small-molecule drugs). However, these options need several months to years for their development. Because of the urgent need to alleviate the COVID-19 pandemic, the use of repurposed existing antiviral drugs approved for treatment of other viral infections such as human immunodeficiency virus (HIV), hepatitis B virus, hepatitis C virus, and influenza is somewhat promising, 12 based on previous successes of the therapeutic treatment with two relevant human coronaviruses, SARS-CoV and MERS-CoV. According to numerous previous studies, 1,7,13−16 the nonstructural protein of coronavirus, in particular, main proteases or 3C-like proteases (3CL pro ), is considered an attractive drug target for the treatment of coronavirus infection. The role of this protease involves the proteolytic processing of the replicase polyprotein and is crucial for viral replication and maturation. 17 Moreover, 3CL pro has a similar common cleavage site among coronaviruses. 18 The sequence alignment of SARS-CoV-2 3CL pro (see Figure S1 ) shows that the SARS-CoV-2 proteinase is highly conserved compared to that of SARS-CoV with a 96.1% sequence identity.

A combination of the two approved drugs for HIV infection, lopinavir and ritonavir (KALETRA), has been reported to be active toward SARS and MERS. 14, 19 Both anti-HIV drugs were initially purposed to inhibit 3CL pro of SARS-CoV and MERS-CoV, and they appeared to be related to clinical benefits of patients with SARS in a nonrandomized open-label trial. 17 Although ritonavir is a protease inhibitor, it is generally used to inhibit cytochrome P450 3A4 and markedly increases the plasma concentrations of other protease inhibitors. 20 Nevertheless, whether HIV protease inhibitors could effectively target SARS-CoV-2 3CL pro is under debate. This is based on the fact that HIV protease is from the aspartic protease family, whereas SARS-CoV-2 3CL pro belongs to the cysteine protease family. Previously, a theoretical study of the molecular interaction of lopinavir and ritonavir with 3CL pro of SARS-CoV suggested that these two drugs could bind well at the substrate-binding pocket of SARS-CoV 3CL pro . 15 To date, the three-dimensional structure of SARS-CoV-2 3CL pro in a complex with lopinavir and ritonavir has not been reported. Thus, in our study, we aimed to investigate the binding interactions of lopinavir and ritonavir with the SARS-CoV-2 proteinase using both molecular modeling and quantum chemical methods. It is our hope that this information can be useful for the future design or development of more specific inhibitors for the treatment of human coronaviruses. Biochemistry pubs.acs.org/biochemistry Article with lopinavir and ritonavir bound to protomer A, the positions of the original peptidelike inhibitor were changed to the corresponding drug for each P position ( Figure 1B ,C). This modification was performed according to the similar orientation with the template inhibitor using the small molecules tool implemented in Accelrys Discovery Studio 2.5 (Accelrys Inc.). The protonation states of all ionizable amino acids were assigned at pH 7.4 using the H++ web server, 22 except for the catalytic residue H41 that was set as the neutral form with a protonated delta position (HID type of AMBER format) in accordance with the common reaction mechanism of cysteine protease. 23 The chemical structures of lopinavir (ZINC3951740) and ritonavir (ZINC3944422) were downloaded from the ZINC15 database. 24 The electrostatic potential (ESP) charges of both ligands were calculated with the HF/6-31G* level of theory using the Gaussian09 program. 25 The antechamber and parmchk modules of AMBER16 were used to generate the restrained ESP charges and missing parameters of the two drugs, respectively. The bonded and nonbonded parameters for the protein and ligand were treated with the AMBER ff14SB force field 26 and generalized AMBER force field version 2 (GAFF2), 27 accordingly. Missing hydrogen atoms were added using the LEaP module implemented in AMBER16. Afterward, the TIP3P water model 28 was used to solvate each system with a minimum distance of 10 Å between the protein surface and the solvation box edge, and the box dimensions were set to approximately 114 Å × 97 Å × 92 Å. The sodium ions were then randomly added to neutralize the simulated systems. The added hydrogen atoms and water molecules were minimized using 500 steps of steepest descent (SD) followed by 1500 steps of conjugated gradient (CG) methods before running the MD simulations, while the rest of the molecules were held fixed. Then, the protein and ligand were minimized by SD (500 iterations) and CG (1500 iterations) methods with constrained solvent molecules. Finally, the whole complex was fully minimized using the same procedure. Molecular Dynamics Simulations. Each system was simulated under the periodic boundary condition with the isothermal−isobaric (NPT) scheme, as previously described. 29−32 Briefly, a cutoff distance for nonbonded interactions was set to 10 Å, while the particle mesh Ewald summation method 33 was employed to treat the electrostatic interactions. The SHAKE algorithm 34 was used to constrain all covalent bonds involving hydrogen atoms. A 2 fs simulation time step was used throughout the MD simulation. The temperature and pressure were controlled by the Langevin thermostat 35 with a collision frequency of 2 ps −1 and the Berendsen barostat 36 with a pressure-relaxation time of 1 ps. For the heating step, each simulated system was gradually heated from 10 to 310 K for 200 ps with a harmonic positional restraint of 30.0 kcal mol −1 Å −2 applied to the Cα atoms of the protein. To equilibrate the system, each complex was then subjected to four steps of restrained MD simulations at 310 K with harmonic restraints of 30, 20, 10, and 5 kcal mol −1 Å −2 for 1300 ps in total and another 200 ps without any restraint. Subsequently, the entire system was simulated under the NPT ensemble (310 K and 1 atm) until reaching 100 ns. The MD trajectories were saved every 10 ps. The calculations in terms of the root-mean-square displacement (RMSD), the number of protein−drug hydrogen bonds (# Hbonds), and the number of atomic contacts (# atom contacts) with the drug molecule were used to verify the stability of all investigated models as well as the structural features of each complex. The H-bond interactions were calculated using two criteria: (i) distance between the hydrogen donor (HD) and acceptor (HA) of ≤3.5 Å and (ii) HD−H···HA angle of ≥150°. The # atom contacts were counted from the number of 3CL pro atoms within 3.5 Å of each drug. To evaluate the binding affinity and the key binding residues involved in ligand binding of the protein−ligand complexes, the total binding free energy (ΔG bind ) and per-residue decomposition free energy (ΔG bind residue ) calculations based on molecular mechanics/Poisson−Boltzmann (generalized Born) surface area [MM/PB(GB)SA] methods were performed on 100 MD snapshots extracted from the last 20 ns of the MD production phase. It should be noted that the protein−ligand interactions and the binding free energies were carried out using the CPPTRAJ 37 and MMPBSA.py 38 modules of AMBER16, respectively. Furthermore, the intermolecular interactions between the drug and its binding residues at the atomic level were described by pair interaction energy decomposition analysis (PIEDA) based on the fragment molecular orbital (FMO) method at the secondorder Møller−Plesset perturbation energy and the 6-31G* level of theory (FMO-MP2/6-31G*) using GAMESS. 39 The solvation effect was also treated with a polarizable continuum model (PCM were higher than those of the lopinavir model (# H-bonds of 2 ± 1 and # atom contacts of 14 ± 4), suggesting that ritonavir was more susceptible to SARS-CoV-2 3CL pro (discussed in more detail below). In this work, the MD trajectories from 80 to 100 ns were thus extracted for further analysis in terms of (i) the binding affinity between lopinavir or ritonavir and SARS-CoV-2 3CL pro , (ii) key binding residues involved in drug binding, (iii) protein−drug H-bonding, and (iv) water accessibility at the enzyme active site. Biochemistry pubs.acs.org/biochemistry Article Predicted Inhibitory Efficiency. The susceptibility of lopinavir and ritonavir to SARS-CoV-2 3CL pro was estimated using the MM/PB(GB)SA approach on 100 snapshots extracted from the last 20 ns of simulation. Note that the MM/PBSA and MM/GBSA results in Table 1 provided a similar trend in the binding free energy predictions.

According to the molecular mechanics (ΔE MM ) calculations, we found that van der Waals (vdW) interaction is the main force inducing molecular complexation with SARS-CoV-2 3CL pro of both lopinavir (ΔE vdW of −50.29 ± 0.62 kcal/mol) and ritonavir (−74.09 ± 0.50 kcal/mol) and is ∼2−3-fold stronger than the electrostatic attraction (ΔE ele values of −19.68 ± 0.50 and −23.35 ± 0.56 kcal/mol, respectively). This finding was in a good agreement with the ΔE MM results of (i) these two anti-HIV drugs in complex with SARS-CoV 3CL pro15 and (ii) darunavir and amprenavir binding to the HIV-1 protease. 43 Taken together with the solvation effect and entropic term, the binding affinity (ΔG bind ) of ritonavir with SARS-CoV-2 3CL pro (−14.93 ± 1.83 and −27.78 ± 1.82 kcal/mol taken from the MM/PBSA and MM/GBSA methods, respectively) was relatively higher than that of another drug (−10.89 ± 1.89 and −13.83 ± 1.91 kcal/mol, respectively). The predicted results suggested that Key Residues for the Repurposed HIV Drug to Combat COVID-19. To evaluate the key residues involved in anti-HIV drug binding at the active site of SARS-CoV-2 3CL pro , the ΔG bind residue calculation based on the MM/GBSA method was performed. The total energy contribution from each residue associated with drug binding of both complexes is plotted in Figure 3 , and the drug orientation in the enzyme active site is illustrated in the right panel, in which the contributing amino acids are colored according to their ΔG bind residue values. It is important to note that only residues exhibiting an energy stabilization of ≤−1.0 kcal/mol were taken into account.

The obtained results revealed that there were four (M49, M165, P168, and Q189) and nine residues (L27, H41, M49, F140, N142, G143, H164, M165, and E166) that were important for the binding of lopinavir and ritonavir, respectively. The more strongly contributing residues found in the SARS-CoV-2 3CL pro −ritonavir complex were in accordance with the results mentioned above (Figure 2 and Table 1 ). Similarly, it was reported that the SARS-CoV 3CL pro residues (i) M49 and M165 and (ii) E166 strongly stabilized PJ207, a quinazolinecontaining compound, mainly through hydrophobic interaction and H-bond formation, respectively. 44 In line with this finding, our ΔG bind residue calculation showed that the phenyl ring at the P1 position of lopinavir and the thiazole ring at the P2 position of ritonavir were inserted into the S2 pocket of SARS-CoV-2 3CL pro , forming hydrophobic contacts with residues M49 and M165 (Figure 3) , and the O 1 atom of ritonavir was stabilized by the -NH group of E166 via H-bond formation ( Figure 6 , discussed below). It is of note that only ritonavir could interact with the catalytic residue H41 45 and the oxyanion hole residues N142 and G143 46 (ΔG bind residue of −1.4 kcal/mol for each residue), suggesting that the molecular structure of ritonavir fitted well within the active site of SARS-CoV-2 3CL pro . The obtained information was supported by the well-aligned structures of ritonavir over the last 20 ns simulation (Figure 4) , whereas a large fluctuation of the P2′ site was detected in lopinavir.

In terms of the contribution from the electrostatic (ΔE ele + ΔG polar , black line) and vdW (ΔE vdW + ΔG nonpolar , red line) energies from each residue, it can be seen from Figure 5 that the main energy contribution for stabilizing the HIV-1 protease inhibitors lopinavir and ritonavir was the vdW energy (≲−4.0 kcal/mol), especially for residues M49, M165, and Q189, whereas the electrostatic contribution was observed in the range of approximately −1.0 to 2.0 kcal/mol as related to the ΔE MM calculations (see Table 1 ). However, there is a common concern about the drawbacks of the molecular mechanics calculations, in particular electronic properties. The FMO-MP2/PCM/6-31G* calculation was additionally performed on the last snapshot of each complex to investigate the protein−drug interactions at the enzyme active site. The advantage of this method is known to include the electron correlation, which trustworthily describes the hydrophobic effect and hydrogen bond interaction between the ligand and individual residue. 40, 47, 48 Figure 6 highlights that Biochemistry pubs.acs.org/biochemistry Article ritonavir binding with an energy stabilization of approximately −12 to −20 kcal/mol, whereas residues G143, S144, C145, and D187 showed less energy stabilization of approximately −5 to −7 kcal/mol, most likely through dispersion and electrostatic interactions, except for residue E166, for which the impact of the solvation effect was predominantly found on the two drugs binding to SARS-CoV-2 3CL pro . As compared to the recently reported potent α-ketoamide inhibitor (13b) bound to SARS-CoV-2 3CL pro , 49 the anti-HIV drugs lopinavir and ritonavir lack (i) the P3 moiety, (ii) an αketoamide group located between positions P1 and P1′, and (iii) polar moieties on the phenyl ring in the P1 region. However, the phenyl ring at the P1′ site of both HIV-1 protease inhibitors and 13b remains the same, and the P2 (larger and more hydrophilic than 13b) and P2′ (found only in HIV-1 protease inhibitors) regions of lopinavir and ritonavir strongly interacted with SARS-CoV-2 3CL pro at the S2 and S2′ pockets, respectively ( Figure 3) . Accordingly, on the basis of this evidence, we proposed a rational design of novel protease inhibitor(s) derived from lopinavir and ritonavir to enhance the binding efficiency with SARS-CoV-2 3CL pro as follows: (i) changing the phenyl ring in the P1 region to the γ-lactam ring to increase the extent of Hbond formation with residues F140, H163, and E166, (ii) introducing P3 polar moieties (e.g., pyridone ring) to form Hbonds with the negatively charged E166, and (iii) adding the reactive α-ketoamide group located between positions P1 and P1′ to covalently bond with the catalytic residue C145, as depicted in Figure 7 .

Protein−Drug Hydrogen Bonding. Although the protein−drug interactions were primarily contributed by the vdW interactions, the formation of H-bonds between both anti-HIV drugs and their surrounding residues in the active site of SARS-CoV-2 3CL pro could be an important factor in the inhibition of this targeted enzyme. To monitor such interaction, the percentages of H-bond occupations are plotted in Figure 8 , whereas the representative structures determined from the last MD snapshot are depicted in Figure 9 . As expected, H-bond formation (three to four H-bonds) between the drugs and the surrounding residues inside the active site of SARS-CoV-2 3CL pro was observed. In the case of lopinavir, there were three H-bonds: It can be noticed that the importance of residues E166 and Q189 also agreed well with the reported binding of such HIV-1 protease inhibitors to SARS-CoV. 15 Notably, ritonavir showed a slightly higher level of Hbond formation with 3CL pro , and its P1′ site was stabilized by the oxyanion hole residues N142 and G143.

Solvent Accessibility in the 3CL pro Active Site. As the active site of SARS-CoV-2 3CL pro is located near the solventexposed area, water molecules might play a role in stabilizing protein−ligand interactions. To characterize the effect of water accessibility at the 3CL pro active site, the solvent-accessible surface area (SASA) (Figure 10 ) calculations were performed on the residues within 4 Å of each anti-HIV drug. Moreover, the radial distribution function (RDF) (Figure 11 ) of water oxygens toward all heteroatoms of lopinavir and ritonavir was used to verify the number of water molecules approaching the ligands.

Our complex model of the SARS-CoV-2 3CL pro homodimer contained the anti-HIV drugs binding only to protomer A. It can be seen from Figure 10 that the SASAs for protomer B (blue) were 883.81 ± 75.24 and 918.15 ± 110.03 Å 2 for the lopinavir and ritonavir systems, respectively. Upon molecular complexation in protomer A (yellow), the SASAs of both lopinavir (500.21 ± 67.38 Å 2 ) and ritonavir (451.60 ± 61.62 Å 2 ) systems dramatically decreased in a manner similar to those of other studies. 50−52 By considering the RDF results, we found that the first peak at ∼3 Å of the lopinavir system (up to ∼2) was slightly higher than that of the ritonavir system (up to ∼1.4), indicating that accessible water molecules were more pronounced in the SARS-CoV-2 3CL pro −lopinavir complex. As the H-bond water network, protein···water···drug, also plays a role in stabilizing the protein−ligand complex, 53 we further investigated the H-bond water bridges around the heteroatoms of both ligands using the same structural criteria of H-bonds described elsewhere. The obtained results demonstrated that there was only one bridging water coordinating with (i) lopinavir (O 2 ) and E166 as well as (ii) ritonavir (O 4 ) and N142 with a very low percentage of occupancy (∼5−13%), suggesting that the bridging water did not make a significant contribution to mediating the H-bond network of protein−ligand binding.

In this work, the binding pattern and susceptibility of the two HIV-1 protease inhibitors lopinavir and ritonavir in complex with SARS-CoV-2 3CL pro were fully revealed by all-atom MD simulations, binding free energy estimation, and PIEDA based on the MM/PB(GB)SA and FMO-MP2/PCM/6-31G* calculations, respectively. According to ΔG bind prediction, the susceptibility against SARS-CoV-2 3CL pro of ritonavir was somewhat higher than that of lopinavir, supported by energy stabilization from individual residues that resulted from both methods: (i) M49, M165, P168, and Q189 from MM/GBSA for lopinavir and L27, H41, M49, F140, N142, G143, H164, M165, and E166 from MM/GBSA for ritonavir and (ii) H41, A46, M49, E166, L167, L187, Q189, A191, and A193 from FMO-MP2/PCM/6-31G* for lopinavir and N142, G143, S144, C145, M165, E166, D187, and Q189 from FMO-MP2/PCM/6-31G* for ritonavir. In addition, the oxyanion hole residues N142 and G143 were found to interact with ritonavir via hydrogen bonds. From the FMO-MP2/PCM/6-31G* data, the electrostatics, dispersion, and charge transfer were considered as the important interactions for drug binding. The obtained results demonstrated how repurposed anti-HIV drugs could be used to combat COVID-19 and how fundamental knowledge at the atomic level could also be helpful for the further design or development of more specific inhibitors in treating human coronaviruses.

The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acs.biochem.0c00160.

Amino acid sequences and structural comparison (PDF)

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Full-genome evolutionary analysis of the novel corona virus (2019-nCoV) rejects the hypothesis of emergence as a result of a recent recombination event

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

Coronavirus genome structure and replication

Biological and genetic characterization of a hemagglutinating coronavirus isolated from a diarrhoeic child

Drug design targeting the main protease, the Achilles' heel of coronaviruses

Epidemiologic clues to SARS origin in China

Middle east respiratory syndrome coronavirus (MERS-CoV): Announcement of the coronavirus study group

Epidemiology, Genetic Recombination, and Pathogenesis of Coronaviruses

Approved antiviral drugs over the past 50 years

Lopinavir/ritonavir in the treatment of human immunodeficiency virus infection

Role of lopinavir/ ritonavir in the treatment of SARS: Initial virological and clinical findings

Molecular dynamic simulations analysis of ritronavir and lopinavir as SARS-CoV 3CLpro inhibitors

Potential inhibitors against 2019-nCoV coronavirus M protease from clinically approved medicines

Coronaviruses-drug discovery and therapeutic options

Coronavirus main proteinase (3CLpro) Structure: Basis for design of anti-SARS drugs

Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon-β1b (MIRACLE trial): Study protocol for a randomized controlled trial

Structure of M pro from COVID-19 virus and discovery of its inhibitors

H++ 3.0: Automating pK prediction and the preparation of biomolecular structures for atomistic molecular modeling and simulations

Cysteine proteases and their inhibitors

ZINC 15 -Ligand Discovery for Everyone

Improving the Accuracy of Protein Side Chain and Backbone Parameters from ff99SB

Development and testing of a general Amber force field

Comparison of simple potential functions for simulating liquid water

Key binding and susceptibility of NS3/4A serine protease inhibitors against hepatitis C virus

Butoxy Mansonone G Inhibits STAT3 and Akt Signaling Pathways in Non-Small Cell Lung Cancers: Combined Experimental and Theoretical Investigations

Binding recognition of substrates in NS2B/NS3 serine protease of Zika virus revealed by molecular dynamics simulations

Low susceptibility of asunaprevir towards R155K and D168A point mutations in HCV NS3/4A protease: A molecular dynamics simulation

Particle mesh Ewald: An N·log(N) method for Ewald sums in large systems

Numerical integration of the cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes

Synchronization of trajectories in canonical molecular-dynamics simulations: Observation, explanation, and exploitation

Molecular dynamics with coupling to an external bath

PTRAJ and CPPTRAJ: Software for processing and analysis of molecular dynamics trajectory data

MMPBSA.py: An efficient program for end-state free energy calculations

Use of approximate integrals in ab initio theory. An application in MP2 energy calculations

Fragment molecular orbital method: Analytical energy gradients

Pair interaction energy decomposition analysis

Multiple virtual screening strategies for the discovery of novel compounds active against dengue virus: A hit identification study

Revealing Origin of Decrease in Potency of Darunavir and Amprenavir against HIV-2 relative to HIV-1 Protease by

Inhibitors of SARS-3CLpro: virtual screening, biological evaluation, and molecular dynamics simulation studies

Dynamically-driven inactivation of the catalytic machinery of the SARS 3C-like protease by the N214A mutation on the extra domain

A structural view of the inactivation of the SARS coronavirus main proteinase by benzotriazole esters

Application of singular value decomposition to the inter-fragment interaction energy analysis for ligand screening

Application of the fragment molecular orbital method to discover novel natural products for prion disease

Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved αketoamide inhibitors

Structural insights into Rab21 GTPase activation mechanism by molecular dynamics simulations

Atomistic mechanisms underlying the activation of the G proteincoupled sweet receptor heterodimer by sugar alcohol recognition

Two zinc-binding domains in the transporter AdcA from Streptococcus pyogenes facilitate high-affinity binding and fast transport of zinc

Effect of electrostatic polarization and bridging water on CDK2-ligand binding affinities calculated using a highly efficient interaction entropy method